Chronic subdural hematoma represents one of the most frequent neurosurgical emergencies encountered in elderly populations worldwide. Although standard surgical evacuation via burr hole craniotomy provides immediate symptomatic relief, high recurrence rates continue to challenge neurosurgeons and critical care physicians. Clinicians actively explore adjunctive pharmacotherapies to suppress microvascular leakage and hyperfibrinolysis within the subdural neo-membrane. In this context, utilizing tranexamic acid chronic subdural hematoma management protocols offers a promising avenue to decrease repeat operative interventions. Recent clinical data from a propensity score-matched analysis provide valuable insights into postoperative recurrence risk, hematoma volume resolution, and safety endpoints in surgical cohorts.

Understanding the Pathophysiology of Recurrent Subdural Collections

Chronic subdural hematomas develop when bridging veins rupture, typically following minor head trauma in elderly patients with progressive cerebral atrophy. Subsequently, an inflammatory cascade triggers the formation of a vascularized neo-membrane over the hematoma cavity. This neo-membrane produces excessive tissue plasminogen activator, which continually activates local fibrinolysis and sustains microvascular bleeding. Consequently, the hematoma enlarges gradually over weeks, creating mass effect, cognitive decline, focal neurological deficits, and increased intracranial pressure.

Standard burr hole craniotomy effectively evacuates the initial fluid collection and relieves intracranial hypertension. However, surgical drainage alone does not completely eradicate the underlying inflammatory neo-membrane. Therefore, persistent oozing from fragile neo-vessels frequently causes hematoma re-accumulation, requiring repeat surgical revision in up to twenty percent of patients. In addition, elderly patients frequently have comorbidities, including anticoagulant or antiplatelet use, which exacerbate hemorrhage risks. Thus, halting the self-perpetuating cycle of local fibrinolysis and fragile neovascularization remains essential. Clinicians must address both mechanical compression and ongoing biochemical hyperfibrinolysis to optimize long-term patient recovery.

Mechanism of Action: Tranexamic Acid Chronic Subdural Hematoma Pathways

Tranexamic acid functions primarily as a synthetic lysine analog that competitively inhibits plasminogen activation. By blocking the lysine-binding sites on plasminogen molecules, tranexamic acid prevents its conversion into active plasmin. As a result, the drug effectively halts fibrin degradation and stabilizes existing hemostatic clots. In the specific setting of tranexamic acid chronic subdural hematoma therapy, this antifibrinolytic action directly suppresses the enzymatic hyperfibrinolysis present within the subdural membrane fluid.

Furthermore, researchers recognize that tranexamic acid exerts significant anti-inflammatory and anti-angiogenic properties beyond simple hemostasis. Because plasmin normally stimulates inflammatory cytokine production and vascular endothelial growth factor release, inhibiting plasmin dampens localized inflammation. Consequently, adjuvant tranexamic acid therapy helps seal leaking capillaries and inhibits abnormal neo-vessel formation within the hematoma outer membrane. By administering this agent postoperatively, surgeons aim to arrest recurrent micro-hemorrhages while the brain parenchyma slowly re-expands. Therefore, tranexamic acid serves a dual therapeutic function: preserving early clot integrity and attenuating chronic neo-membrane inflammation throughout the postoperative recovery phase.

Key Findings: Recurrence Rates and Revision Surgery Outcomes

The propensity score-matched investigation evaluated adult patients undergoing burr hole craniotomy with subdural drainage across a twelve-year period. Researchers matched seventy-three patients receiving postoperative tranexamic acid with seventy-three surgical controls who received surgery alone. Baseline clinical characteristics, including age, antithrombotic therapy, and preoperative midline shift, matched evenly between groups. Notably, the primary endpoint was revision surgery for recurrent hematoma within ninety days following the initial evacuation.

The study demonstrated a notable reduction in surgical recurrence among patients receiving tranexamic acid. Specifically, revision surgery occurred in only 8.2% of the tranexamic acid cohort compared to 19.2% of the control cohort. Statistical analysis revealed an odds ratio of 0.40 (95% CI 0.14 to 1.12; p = 0.042), indicating a substantial protective trend against reoperation. However, clinicians must interpret the statistical significance cautiously because the confidence interval marginally crossed unity. Additionally, the median time to revision was 8 days in the tranexamic acid group versus 11 days in the control group. Overall, these clinical observations suggest that adjuvant tranexamic acid may effectively decrease secondary intervention rates in routine practice.

Hematoma Volume Dynamics and Postoperative Evolution

Beyond evaluating surgical revision rates, the study carefully tracked quantitative hematoma volume dynamics using serial computed tomography imaging. Investigators measured volumetric data preoperatively, immediately after surgery, and at thirty-day follow-up assessments. Interestingly, both study arms exhibited comparable baseline hematoma volumes before intervention. Following burr hole drainage, both groups achieved substantial and rapid reductions in intracranial fluid volume.

However, postoperative adjuvant tranexamic acid did not produce significant differences in absolute volume reduction compared to surgery alone. Specifically, one-month follow-up imaging demonstrated nearly identical residual hematoma volumes in both cohorts. These radiological observations indicate that tranexamic acid does not accelerate the physical resorption of residual subdural fluid collections. Instead, its primary clinical benefit appears to stem from preventing sudden, symptomatic micro-rebleeding events that prompt revision surgery. Therefore, clinicians should not expect rapid radiographic clearance from tranexamic acid alone; rather, they should view the medication as a biochemical stabilizer that prevents recurrence while the brain gradually re-expands over several weeks.

Safety Profiles, Mortality, and Thromboembolic Considerations

Evaluating pharmacological safety remains crucial whenever clinicians prescribe antifibrinolytic therapy to elderly patients with cardiovascular comorbidities. In this investigation, all-cause mortality served as a key secondary safety outcome. Fortunately, researchers observed zero deaths in the tranexamic acid group, compared to one death (1.4%) in the control cohort. Moreover, the matched analysis identified no significant increase in systemic thromboembolic events, such as deep vein thrombosis, pulmonary embolism, or ischemic stroke.

These safety findings align with several recent systematic reviews examining tranexamic acid in neurosurgical patients. Because surgeons administered conservative oral dosing regimens over at least thirty days, the drug exerted targeted antifibrinolytic actions without inducing severe systemic hypercoagulability. Nevertheless, neurosurgeons and geriatricians must maintain vigilance when evaluating patients with pre-existing vascular disease, active malignancies, or severe renal impairment. Careful baseline screening and personalized risk stratification remain vital steps before initiating prolonged postoperative antifibrinolytic therapy. Consequently, the observed safety profile supports further evaluation of tranexamic acid in larger prospective multicenter clinical trials.

Translating Evidence into Clinical Neurosurgical Practice

The findings from this propensity-matched study provide compelling, hypothesis-generating support for incorporating adjuvant tranexamic acid into chronic subdural hematoma treatment algorithms. In routine practice, elderly patients presenting with brain compression frequently struggle with recurrence due to cerebral atrophy and fragile vasculature. Combining burr hole craniotomy with targeted postoperative antifibrinolytics offers a cost-effective, readily available strategy to optimize clinical outcomes and reduce hospitalization readmissions.

Nevertheless, practitioners must recognize certain methodological limitations inherent to retrospective, single-center study designs. Although propensity score matching minimizes baseline confounding, unmeasured variables and physician selection bias might still influence therapeutic outcomes. Furthermore, establishing optimal dosing regimens, exact administration timing, and treatment durations requires standardized investigation. Clinicians should await definitive results from ongoing phase III randomized controlled trials before universally changing institutional guidelines. In the interim, neurosurgical multidisciplinary teams may consider tranexamic acid on a case-by-case basis for high-risk patients who exhibit high recurrence potential or heightened reoperation morbidity.

How does tranexamic acid reduce recurrence in chronic subdural hematoma?

Tranexamic acid competitively inhibits plasminogen activation, thereby suppressing local hyperfibrinolysis and tissue degradation in the hematoma neo-membrane. Furthermore, it attenuates vascular inflammation and microvascular leakage. This dual action stabilizes formed clots, prevents recurrent micro-hemorrhages from fragile neo-vessels, and significantly lowers the likelihood of requiring repeat revision surgery.

Does postoperative tranexamic acid accelerate hematoma volume clearance?

Clinical studies show that tranexamic acid does not significantly accelerate physical hematoma volume reduction compared to surgery alone. Instead, surgical drainage achieves primary volumetric reduction. Tranexamic acid functions primarily as a biochemical stabilizer that prevents re-bleeding and secondary hematoma expansion while the brain re-expands over subsequent weeks.

What are the primary safety concerns when prescribing tranexamic acid to elderly patients?

The primary concern involves potential systemic thromboembolic complications, including deep vein thrombosis, pulmonary embolism, myocardial infarction, and ischemic stroke. However, clinical studies with low-dose regimens show favorable safety profiles. Clinicians must still perform individualized risk assessments, particularly in patients with severe renal impairment or underlying thromboembolic disorders.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals must exercise independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Scheer M et al. Revision rate and postoperative volume development of chronic subdural hematomas after burr hole craniotomy in combination with tranexamic acid vs. surgery alone - a single-center propensity score-matched analysis. BMC Neurol. 2026 Jun 08. doi: 10.1186/s12883-026-05003-3. PMID: 42260407.


2. Iorio-Morin C, Blanchard J, Richer M, Mathieu D. Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial. Trials. 2016;17(1):235.


3. Edlmann E, Giorgi-Coll S, Whitfield PC, Carpenter KL, Hutchinson PJ. Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy. J Neuroinflammation. 2017;14(1):108.